SK Holdings has entered a strategic partnership with the pharmaceutical company builder as the latter unveils a new targeted protein degradation platform.
Switzerland-based pharmaceutical company builder Roivant Sciences has spun off a targeted protein degradation platform with $200m of equity funding from SK Holdings, the holding company for diversified conglomerate SK Group.
The as yet unnamed platform is focused on targeted protein degraders, which utilise the human body’s protein disposal system to deliver more efficient and effective dosing of treatments, also facilitating the targeting of proteins that are difficult to drug.
The platform is being used to discover drug candidates targeted at…
